A3.31 Withdrawal Form

1.	Has the participant withdrawn from:	Treatment Only	(ie Placebo / Mirtazapine / Sertraline)	0
		Trial	(ie Treatment and Follow-Up)	1
2.	Brief description of the reason for withdrawal (attach additional sheets if necessary)			
3.	Date of withdrawal	Day Month Year		
4.	Reason for withdrawal	Eligibility criterion no longer met		
	(Circle all that apply)	(Consolf ii		1
		(Specify:)		2
		Death of participant (SAE no)		2
		Other adverse event (AE / SAE no) Deterioration of pre-existing medical condition Poor adherence to treatment		3
				4
				5
			efficacy of medication	6
		Unable to locate	· · · · · · · · · · · · · · · · · · ·	7
		Unable to locate a		8
		Other (Specify: _)	9
5.	Withdrawal decision initiated by:	Chief Investigator		1
	(Circle all that apply)	Principal Investigator		2
		Referring Investigator		3
		Carer		4
		Participant		5
		Other (Specify: _)	6
6.	Would the Principal Investigator have independently recommended withdrawal from treatment	No		0
		Yes		1
7.	Permission given to use data collected:	No. use of all data	a collected to date denied	1
	J	•	ssion to use data up to withdrawal	
		'.)	2
		(Specify:	use all data up to withdrawal	3
			•	4
		Yes, permission to collect and use all follow-up data 4		7
8.	Treatment code broken:	No		0
	(Not unless absolutely necessary)	Yes (Emergency l	Jnblinding Request no)	1
9.	Signature of Research Worker:	Signature of Principal Investigator		

Page 142 of 148 EUDRACT Number: 2006-000105-38